Analysts Set Illumina, Inc. (NASDAQ:ILMN) PT at $199.12

Illumina, Inc. (NASDAQ:ILMN) has been assigned a consensus rating of “Hold” from the eighteen ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $199.1250.

A number of equities analysts have weighed in on the company. Evercore restated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Canaccord Genuity Group upped their price objective on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday, August 3rd. Finally, Argus raised their target price on shares of Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd.

Illumina Stock Up 3.0%

ILMN opened at $228.93 on Friday. The company has a fifty day moving average price of $202.61 and a 200-day moving average price of $164.50. The firm has a market capitalization of $34.57 billion, a P/E ratio of 42.71, a price-to-earnings-growth ratio of 3.15 and a beta of 1.46. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. Illumina has a one year low of $88.00 and a one year high of $236.00.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts expect that Illumina will post 5.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 2,062,465 shares of company stock valued at $436,589,802. 2.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. BlackRock Inc. bought a new stake in Illumina during the second quarter worth about $3,374,423,000. Capital World Investors increased its position in shares of Illumina by 0.6% during the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after purchasing an additional 124,323 shares during the last quarter. WCM Investment Management LLC increased its position in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA purchased a new position in shares of Illumina during the 2nd quarter valued at about $617,981,000. Finally, Geode Capital Management LLC raised its holdings in shares of Illumina by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after buying an additional 130,139 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.